Product photoshopped on Pharma forum and social media. Matthew Taylor is involved
Screengrabs downloaded by Abbvie Legal.
Screengrabs downloaded by Abbvie Legal.
Viekira Defamation On Web
- Thread starter anonymous
- Start date
-
- Tags
- None
Co-Founder and serves as a Portfolio Manager at Kortright Capital Partners LP, Kortright Opportunity Fund LP. Mr. Taylor served as a Portfolio Manager of Advisors Series Trust - Vivaldi Orinda Hedged Equity Fund. Prior to this, he was employed at Barclays. Mr. Taylor served as a Managing Director at Och-Ziff Capital Management Group LLC. He serves as the Vice Chairman and Director of Free Arts NYC, Now runs Pharma forum out of Carson City.
?How AbbVie Could Hammer Gilead's Hepatitis C Franchise
Reprints
AbbVie (ABBV) is likely to swipe significant hepatitis C drug share from Gilead Sciences(GILD) with an eight-week regimen — four weeks shorter than a triple-pill treatment from Gilead, an analyst said Wednesday.
The Food and Drug Administration on Tuesday approved Gilead's combination of sofosbuvir, velpatasvir and voxilaprevir as a 12-week regimen for patients of all genotypes. The combo has been recommended for approval as an eight-week course in Europe. It is approved in the U.S. for patients who've already tried one drug.
Meanwhile, AbbVie's combination of glecaprevir and pibrentasvir looks likely to gain approval as an eight-week regimen in all genotypes of hepatitis C and in patients who've never undergone treatment. Gilead's Harvoni is approved as an eight-week regimen, but only in one subset of patients.
"This label places Gilead at a competitive disadvantage to their rival AbbVie, since AbbVie is likely to get approval for all genotypes for an eight-week course," Leerink analyst Geoffrey Porges said in a note to clients. Approval of one genotype is uncertain, he noted.
Gilead is pricing its triple-pill, which will be branded as Vosevi, at $24,920 per bottle. At one bottle per month, that runs up to a 12-week price of about $75,000. That is less costly than Gilead's Harvoni and Sovaldi, but more expensive than Zepatier from Dow component Merck(MRK).
IBD'S TAKE: As its Hepatitis C drug franchise declines, Gilead has said it would be open to an acquisition in the cancer space. But another biotech buy could be a better purchase, says one analyst. Visit IBD's Technology page for a closer look at what Gilead might buy and why.
Most patients will take Vosevi after failing to respond to Harvoni, Zepatier or AbbVie's two-drug combination. AbbVie's drug, on the other hand, is likely to grab approval as a regimen for patients who have never undergone treatment.
Porges expects AbbVie to price its two-pill drug like its Viekira Pak, another hepatitis C combination that goes for about $28,000 per month. AbbVie will aggressively market the two-drug combo against Gilead's Harvoni and Epclusa, he said.
"This strategy is likely to result in significant market share for AbbVie, given the convenience and excellent efficacy of their two-drug combination," he said in a note to clients.
Porges forecasts $140 million in U.S. sales for Vosevi for the second half of 2017 and $300 million per year until 2020, when he expects to see a gradual decline. Outside the U.S., he expects Vosevi to pull in $600 million to $700 million annually from 2018-21.
At the same time, Porges models Gilead's Harvoni and Epclusa as losing market share to AbbVie. He calls for Gilead's hepatitis C drug franchise to represent just 12% of total sales by 2021, falling from half of all sales in 2016.
On the stock market today, Gilead shares climbed 1.45 to close at 72.72. AbbVie popped 0.8% to finish at 72.77.
- ALLISON GATLIN
- 4:26 PM ET
Reprints
AbbVie (ABBV) is likely to swipe significant hepatitis C drug share from Gilead Sciences(GILD) with an eight-week regimen — four weeks shorter than a triple-pill treatment from Gilead, an analyst said Wednesday.
The Food and Drug Administration on Tuesday approved Gilead's combination of sofosbuvir, velpatasvir and voxilaprevir as a 12-week regimen for patients of all genotypes. The combo has been recommended for approval as an eight-week course in Europe. It is approved in the U.S. for patients who've already tried one drug.
Meanwhile, AbbVie's combination of glecaprevir and pibrentasvir looks likely to gain approval as an eight-week regimen in all genotypes of hepatitis C and in patients who've never undergone treatment. Gilead's Harvoni is approved as an eight-week regimen, but only in one subset of patients.
"This label places Gilead at a competitive disadvantage to their rival AbbVie, since AbbVie is likely to get approval for all genotypes for an eight-week course," Leerink analyst Geoffrey Porges said in a note to clients. Approval of one genotype is uncertain, he noted.
Gilead is pricing its triple-pill, which will be branded as Vosevi, at $24,920 per bottle. At one bottle per month, that runs up to a 12-week price of about $75,000. That is less costly than Gilead's Harvoni and Sovaldi, but more expensive than Zepatier from Dow component Merck(MRK).
IBD'S TAKE: As its Hepatitis C drug franchise declines, Gilead has said it would be open to an acquisition in the cancer space. But another biotech buy could be a better purchase, says one analyst. Visit IBD's Technology page for a closer look at what Gilead might buy and why.
Most patients will take Vosevi after failing to respond to Harvoni, Zepatier or AbbVie's two-drug combination. AbbVie's drug, on the other hand, is likely to grab approval as a regimen for patients who have never undergone treatment.
Porges expects AbbVie to price its two-pill drug like its Viekira Pak, another hepatitis C combination that goes for about $28,000 per month. AbbVie will aggressively market the two-drug combo against Gilead's Harvoni and Epclusa, he said.
"This strategy is likely to result in significant market share for AbbVie, given the convenience and excellent efficacy of their two-drug combination," he said in a note to clients.
Porges forecasts $140 million in U.S. sales for Vosevi for the second half of 2017 and $300 million per year until 2020, when he expects to see a gradual decline. Outside the U.S., he expects Vosevi to pull in $600 million to $700 million annually from 2018-21.
At the same time, Porges models Gilead's Harvoni and Epclusa as losing market share to AbbVie. He calls for Gilead's hepatitis C drug franchise to represent just 12% of total sales by 2021, falling from half of all sales in 2016.
On the stock market today, Gilead shares climbed 1.45 to close at 72.72. AbbVie popped 0.8% to finish at 72.77.
2 funni..... must have cut & paste from 2 years ago.....
Freedom Of Speech right here. The King Rat and recruiter of unknowing snitches.
God Bless America. Oh by the way, Abbvie, JNJ, Pfizer and Accarant, ALL have a dossier on them all. Maybe I’ll post more.
You see, once upon a time around 4 years ago a snitch whistleblower targeting
Bill Facteau and Pat Fabian at Acclarent met and brainwashed an inexperienced new forum owner to promote lies and Pfish IP addresses of visitors to promote whistleblowing and encourage defamation. They then doxxed Facteau AGAIN after he took over Earlens. Thier next target was JNJ and the third target was RICK (and FAMILY which in itself was a despicable cowardly move). Then they defamed Abbvies HCV product. Big problem, that photoshopped item made it to Twitter (dumb mistake) They were all identified and sent cease and desist orders. More to come (if cp allows),
Bill Facteau and Pat Fabian at Acclarent met and brainwashed an inexperienced new forum owner to promote lies and Pfish IP addresses of visitors to promote whistleblowing and encourage defamation. They then doxxed Facteau AGAIN after he took over Earlens. Thier next target was JNJ and the third target was RICK (and FAMILY which in itself was a despicable cowardly move). Then they defamed Abbvies HCV product. Big problem, that photoshopped item made it to Twitter (dumb mistake) They were all identified and sent cease and desist orders. More to come (if cp allows),
Fake news... BTW how can anyone defame Vpuke?
Reg user 12002 you’re not the vpuke but you were caught in snare. Go bash Trump.
Here’s the trap and enticing lies under guise on anonymity.
SUBMIT A TIP
Are you aware of fraud occurring at your workplace or previous place of employment?
Speak up, speak out, do the right thing.
Tipline
Thank you for taking the first step to help put an end to the widespread fraud epidemic.
We look forward to hearing from you.
Company or Hospital Name
Fraud Information
Please provide as much detail and corroborative evidence as possible Below you can provide additional information about yourself. By doing so, if we are able to make this fraud count stick, you may be eligible for an enormous financial reward.
Your personal information will NEVER be published on our site or referenced in any way.We take your privacy extremely seriously.
First Name
Last Name
Cell Phone
Yes, but only if you know the assigned algorithm needed to bypass the security sniffer.
Yes you should get good WiFi signal under the Golden Arches. Don’t drop the phone in the deep fryer or burn the burgers whilst posting.
I'm glad the troll named HR finally got a job....